 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

BASKING RIDGE, N.J., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) ( Lisata or the Company ), a clinical-stage pharmaceutical company developing innovative therapies...

Lisata Therapeutics to Present at NobleCon19 Investor Conference

BASKING RIDGE, N.J., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) ( Lisata or the Company ), a clinical-stage pharmaceutical company developing innovative therapies...

Lisata Therapeutics Announces Participation in Upcoming Conferences in November

Lisata Therapeutics, Inc. (NASDAQ:LSTA  Free Report)  Brookline Capital Management issued their Q1 2024 earnings per share estimates for shares of Lisata Therapeutics in a research...

Brokers Issue Forecasts for Lisata Therapeutics, Inc.'s Q1 2024 Earnings (NASDAQ:LSTA)

Lisata Therapeutics, Inc. (LSTA) Q3 2023 Earnings Call Transcript...

Lisata Therapeutics, Inc. (LSTA) Q3 2023 Earnings Call Transcript

Significant clinical progress achieved in studies evaluating LSTA1 including first patients treated in BOLSTER (3 solid tumor basket trial) and continued rapid enrollment in ASCEND Orphan drug...

Lisata Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

BASKING RIDGE, N.J., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) ( Lisata or the Company ), a clinical-stage pharmaceutical company developing innovative therapies...

Lisata Therapeutics to Host Third Quarter 2023 Financial Results Conference Call on Thursday, November 2nd at 4:30 p.m. Eastern Time

Phase 2a double-blind, placebo-controlled, multi-center, randomized study evaluating LSTA1 in combination with standard-of-care versus standard-of-care alone in subjects with advanced solid tumors...

Lisata Therapeutics Announces First Patient Treated in the Cholangiocarcinoma Cohort of the BOLSTER Trial of LSTA1, a Novel Tumor-Targeting and Penetrating Peptide

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Lisata Therapeutics announces EMA granted LSTA1 orphan drug designation

BASKING RIDGE, N.J., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) ( Lisata or the Company ), a clinical-stage pharmaceutical company developing innovative therapies...

Lisata Therapeutics Announces European Medicines Agency Has Granted LSTA1 Orphan Drug Designation for the Treatment of Pancreatic Cancer

Shares of Lisata Therapeutics, Inc. (NASDAQ:LSTA  Get Free Report) traded down 2.8% during trading on Tuesday . The stock traded as low as $2.05 and last traded at $2.07. 16,128 shares were...

Lisata Therapeutics (NASDAQ:LSTA) Trading Down 2.8%

Lisata Therapeutics, Inc. develops biopharmaceuticals. It is engaged in the discovery, development, and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases. It is designed to modify the tumor microenvironment by activating a novel uptake pathway that allows anti-cancer drugs to penetrate solid tumors more effectively. The company is headquartered in Basking Ridge, NJ.

Watchers	9,341
52-Wk Low	$1.95
52-Wk High	$4.53

Market Cap	$20.29M
Volume (M)	556.00
52-Wk High	$4.53
52-Wk Low	$1.95

Current Price	$2.42
Prev Close	$2.44
Open	$2.35
Dividend Yield	0.00%
50-Day Moving Average	$2.17
Beta	0.71
Avg. Volume	18,881.18
PE Ratio	-0.91

52-Week High	$4.53
52-Week Low	$1.95
Market Capitalization	$20.29M
EPS	-$2.68
Price to Book	0.38
Revenue Per Employee	N/A
Enterprise Value/EBITDA	1.42

LSTA Lisata Therapeutics Inc

About

Feed

News

Earnings

Fundamentals